BioMarin buffs up data on hemophilia A gene therapy as FDA decision deadline approaches

BioMarin says its Phase III study for a hemophilia A gene therapy met its primary and secondary endpoints at year three, and it has added …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bio­Marin buffs up da­ta on he­mo­phil­ia A gene ther­a­py as FDA de­ci­sion dead­line ap­proach­es